News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

News

Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer

10/16/2023

Allison Casey

In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...

In a phase 3 clinical trial,...

10/16/2023

Oncology

Videos

RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer

09/23/2023

Featuring Deborah Doroshow, MD, PhD

Featuring Deborah Doroshow, MD, PhD ...

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.

At the Great Debates & Updates...

09/23/2023

Oncology

News

Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation

07/20/2023

Allison Casey

According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.

According to Janssen...

07/20/2023

Oncology

News

Encorafenib Plus Binimetinib Exhibited Clinical Efficacy and Safety Among Patients With BRAFV600E-Mutant Metastatic NSCLC

07/10/2023

Stephanie Holland

Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.

Data from a phase 2 trial show...

07/10/2023

Oncology

News

No Difference in Overall Survival Between Immunotherapy Treatment Lengths Among Patients With Advanced NSCLC

07/10/2023

Amber Denham

Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.

Patients with non–small cell...

07/10/2023

Oncology

News

Low-Dose Spiral Computed Tomography Screening Aids in Reduction of Lung Cancer Mortality

02/22/2023

Derek Cowsert

In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.

In a prospective study, one-off...

02/22/2023

Oncology

News

Optimal Surgery and Treatment Options for Stage 1 Lung Adenocarcinoma/Tumors Spread Through Air Spaces

02/22/2023

Derek Cowsert

A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.

A study found no difference in...

02/22/2023

Oncology

News

High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC

02/16/2023

Derek Cowsert

A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.

A study found high tumor...

02/16/2023

Oncology

News

Early Progression Patterns of Lung Squamous Cell Carcinoma on Computed Tomography Images

02/07/2023

Derek Cowsert

Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.

Findings from a study reveal...

02/07/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology